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Background
Sources. Arsenic in the environment is from
natural and anthropogenic sources. It is com-
monly bound to carbon, iron, oxygen, and
sulfur, forming inorganic and organic arseni-
cals in various oxidation states. The physico-
chemical properties of the many arsenic
species are important determinants of their
potential toxic effects.
Natural. Arsenic, primarily in its inor-
ganic form, is ubiquitously found in soil, air,
and water. More than 200 mineral species
contain arsenic. Arsenic binds with iron and
sulfur to form arsenopyrite. Background lev-
els of arsenic in soil range from 1 to 40 mg/kg
[World Health Organization (WHO) 2001].
Volcanic activity and soil microorganisms
release arsenic into the air. Arsenic air levels
vary throughout the world, with lower levels
in rural areas (0.007–28 ng/m3) and higher
levels in urban areas (3–200 ng/m3) (WHO
2001). Water dissolves minerals that may
release arsenic. Inorganic arsenic (iAs) levels
in seawater and fresh water range from 1 to
10 µg/L (WHO 2001), although levels
1,000 times greater have been recorded
(Nordstrom 2002).
Anthropogenic. The major anthro-
pogenic sources of iAs are nonferrous metal
smelters and coal-burning energy producers.
These processes contaminate air, water, and
soil with iAs. Areas near nonferrous metal
smelters may have air concentrations of
arsenic > 1,000 ng/m3 (WHO 2001). The
manufacture and use of arsenical pesticides
and the improper handling of tailings from
metal mining operations may contaminate
surrounding environments.
Uses. Many commercial, medical, veteri-
nary, and pesticide products contain arsenic.
Arsenic is used in the manufacture of semi-
conductors and glass and as a chemothera-
peutic agent, pesticide, and growth promoter
in farm animals (WHO 2001).
Human Exposure to Arsenic
The diet provides the major amount of
arsenic resulting from its nonoccupational
human exposure. The estimated daily intake
of arsenic in the United States ranges from
2 to 92 µg/day (Tao and Bolger 1998). Levels
of iAs are highest in grains (74 ng/g) and pro-
duce (9 ng/g) (Schoof et al. 1999). For these
foods, iAs constitutes 17–24% of total dietary
arsenic. In contrast, organic arsenic (e.g.,
arsenobetaine) predominates in seafood.
Some seafoods have levels of organic arsenic
in the parts-per-million range (WHO 2001).
Overall, organic arsenic appears to be the
major form of dietary arsenic.
Regarding worldwide public health, the
most important medium for iAs exposure is
drinking water. The source of iAs in drinking
water is primarily geologic (Nordstrom 2002).
Approximately 98% of the U.S. population
ingests drinking water containing < 10 µg
As/L (Chappell et al. 1997). Chronic exposure
to elevated levels of iAs in drinking water is
associated with the development of cancer and
other adverse outcomes (Table 1) [National
Research Council (NRC) 1999, 2001; WHO
2001]. Millions of people worldwide ingest
drinking water contaminated with iAs at levels
> 100 µg/L (Chatterjee et al. 1995; Smith
et al. 2000).
Occupational and nonoccupational expo-
sure to iAs may occur by inhalation at or near
nonferrous smelters, residential and industrial
burning of coal, or pesticide manufacturing
plants and by dermal contact of arsenic-conta-
minated soil or use of arsenic-containing pes-
ticides. Estimates of arsenic air concentrations
at a Tacoma, Washington, copper smelter
exceeded 1,000 µg/m3 during certain periods
of its operation (Enterline et al. 1987).
Wood containing the preservative chro-
mated copper arsenate (CCA) is of recent
interest. In the United States, CCA-treated
wood is found in many residences and play-
grounds. Approximately 5 times more water-
soluble arsenic was found on the hands of
children who played on playgrounds built
with CCA-treated wood than of children who
played on equipment without CCA-treated
wood (Kwon et al. 2004). Due in part to the
concern about exposure to children, the use
of CCA-treated wood in homes and play-
grounds was voluntarily phased out in 2003.
Arsenic and Biomarkers
Biomarkers are classiﬁed as those of exposure,
effect, and susceptibility. For arsenic, bio-
markers of exposure have received the greatest
attention. The most common arsenic bio-
marker of exposure is the analysis of total
arsenic in urine. Urinary porphyrins have also
been proposed as an arsenic biomarker of
exposure (Wang et al. 2002). After chronic
ingestion of iAs, dermatologic lesions may
develop. These lesions have been used as a
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exposure (Chen et al. 2005). Candidate
arsenic effect biomarkers include clastogenicity
in peripheral lymphocytes (Maki-Paakkanen
et al. 1998), micronuclei in oral mucosa and
bladder cells (Biggs et al. 1997), and induction
of heme oxygenase (Del Razo et al. 2001a). A
potential susceptibility biomarker is variability
in arsenic metabolism, which reﬂects polymor-
phisms in the genes that encode the arsenic-
metabolizing enzymes (Vahter 2000).
Disposition of Arsenic
iAs is readily absorbed after oral exposure by
most mammalian species. Absorption of iAs
after inhalation is relatively less than after oral
exposure and is more limited after dermal
exposure (NRC 1999; WHO 2001). After
oral absorption, iAs is primarily methylated in
the liver and excreted in urine by most species.
The metabolic pathway (Equation 1) of iAs
involves sequential two-electron reduction of
AsV species [arsenate, iAsV; monomethyl-
arsonic acid, MMAV; dimethylarsinic acid,
DMAV) followed by oxidative methylation of
AsIII species (arsenite, iAsIII; monomethylarso-
nous acid, MMAIII; dimethylarsinous acid,
DMAIII) (Thomas et al. 2001):
iAsV + 2e– → iAsIII + CH3
+
→ MMAV + 2e– → MMAIII + CH3
+
→ DMAV + 2e– → DMAIII + CH3
+
→ TMAO, [1]
where TMAO is trimethylarsine oxide. The
AsV species are reduced to AsIII species
in vitro nonenzymatically by thiols and enzy-
matically by purine nucleotide phosphorylase
and MMAV reductase (Aposhian et al. 2004;
Thomas et al. 2001). The oxidative methyla-
tion of AsIII species is an enzymatic process.
Arsenic-methylating enzymes from rabbit and
rat liver have been characterized. For in vitro
activity, these enzymes require a thiol and the
methyl donor S-adenosylmethione (Aposhian
et al. 2004; Thomas et al. 2001). The rabbit
enzyme appears to have two distinct methy-
lating activities, one each for iAsIII and
MMAIII. The rat enzyme (AS3MT) has
methyltransferase and reductase activities.
Mice and humans have orthologues of the rat
gene that encodes for AS3MT (Thomas et al.
2004). Regardless of the pathway of arsenic
metabolism, exposure to iAs results in the uri-
nary excretion of predominantly DMAV and
smaller amounts of inorganic and organic AsV
and AsIII species, including TMAO.
Variation in arsenic metabolism.
Metabolism of iAs varies between species and
human populations (Loffredo et al. 2003;
Vahter 2000; Vahter et al. 1995). Dogs and
mice are rapid methylators of iAs and excrete
≥ 80% of the dose as DMAV in urine. Humans
excrete relatively more MMAV than other
species, suggesting that humans are slower
methylators of iAs. This may explain in part
why humans are more sensitive to iAs than
other species. Arsenic excreted by humans tends
to be 10–20% MMAV, whereas that of dogs,
hamsters, mice, rabbits, and rats is 1–5%
MMAV (Vahter 2000). The guinea pig, mar-
moset monkey, and chimpanzee do not methy-
late iAs in vivo (Vahter 2000). The toxicologic
effects of iAs in these animals are not known.
The distribution of arsenic in human urine
is generally 10–30% iAs, 10–20% MMAV,
and 60–70% DMAV (Vahter 2000). Some
populations excrete varying amounts of
MMAV, both considerably less and more, in
urine (Vahter 2000; Vahter et al. 1995). This
suggests that there are genetic polymorphisms
in the regulation of the enzyme(s) that metabo-
lize arsenic, which may lead to differences in
toxicity related to arsenic exposure. However,
the intraindividual variation of iAs metabo-
lism, measured over a 5-day period by Concha
et al. (2002), appears to be stable over time.
Biologically Active Agent
Methylation of iAs to DMAV facilitates
excretion of arsenic. Historically, DMAV has
been identiﬁed as being > 20-fold less acutely
toxic than iAs, suggesting that methylation of
iAs is a detoxication reaction. Improvements
in analytical techniques have resulted in
detection of MMAIII and DMAIII in the urine
of individuals exposed to iAs (Aposhian et al.
2000; Del Razo et al. 2001b; Mandal et al.
2001). Thus, trivalent organic arsenicals are
not the transitory intermediates previously
believed, although their stability is an issue.
MMAIII and DMAIII are potent in vitro and
in vivo toxicants (Petrick et al. 2000, 2001;
Styblo et al. 2000). DMAV, albeit at relatively
high doses, is a multiorgan tumor promoter
in rodents and a complete bladder carcinogen
in rats (Wanibuchi et al. 2004). Methylation
of iAs may not be a mechanism of detoxica-
tion but one of activation.
Arsenic Toxicity
The toxic effects of arsenic are related to its
oxidation state (Hughes 2002; WHO 2001);
trivalent arsenicals are more potent than pen-
tavalent arsenicals. The mechanism of action
for arsenic toxicity is not clearly known.
Trivalent arsenicals react directly with sulf-
hydryls, a key component of many proteins.
Arsenate, pentavalent iAs, has properties simi-
lar to those of phosphate (Dixon 1997).
Arsenate may replace phosphate in critical
biochemical processes that could lead to a
toxic effect.
Animal. The LD50 (median lethal dose) of
iAs in rodents, depending on its oxidation state
and route of administration, ranges from 10 to
90 mg/kg (WHO 2001). Arsenite is 3–4 times
more potent than arsenate. MMAIII adminis-
tered intraperitoneally is more acutely toxic
than iAsIII in hamsters (Petrick et al. 2000).
MMAV and DMAV are less potent than iAs in
rodents, with LD50 values, depending on route
of administration, ≥ 470 mg/kg (WHO 2001).
Adverse noncancerous effects of iAs
include embryo and fetal toxicity, terato-
genicity, genotoxicity (by indirect DNA- or
chromosome-damaging mechanisms), and
cardiovascular toxicity (WHO 2001).
Human. The oral LD50 of iAs in humans is
estimated to be 1–2 mg/kg (Ellenhorn 1997).
Chronic exposure to iAs may result in cuta-
neous, developmental, hematologic, reproduc-
tive, and vascular effects (Table 1) [U.S. Agency
for Toxic Substances and Disease Registry
(ATSDR) 2000; NRC 1999; WHO 2001].
However, the potential for iAs to cause speciﬁc
birth anomalies such as neural tube defects has
been questioned (DeSesso et al. 1998).
The oral reference dose (RfD; a dose con-
sidered safe for regular daily consumption
without adverse health effects) for iAs is
0.3 µg/kg/day, taking into account estimates
of arsenic in food (2 µg As/day) and the
volume of water consumed (4.5 L/day)
[U.S. Environmental Protection Agency
(U.S. EPA) 1993]. This RfD was based pri-
marily on studies of a Taiwanese population,
some of whom ingested high levels of iAs
(400–600 µg/L) in drinking water (Tseng
1977; Tseng et al. 1968). A no observed
adverse effect level of 0.8 µg/kg/day was
derived from the critical effects of hyper-
pigmentation, keratosis, and potential vascu-
lar complications (U.S. EPA 1993).
Arsenic Carcinogenicity
The International Agency for Research on
Cancer (1987) and the U.S. EPA (1993) have
classiﬁed iAs, based on human evidence alone,
as a group 1 and group A carcinogen, respec-
tively. However, the mechanism of action for
iAs-induced carcinogenicity is not known.
Proposed mechanisms include genotoxicity,
oxidative stress, inhibition of DNA repair,
tumor promotion, cocarcinogenesis, cell pro-
liferation, and altered signal transduction or
DNA methylation (Hughes 2002; Kitchin
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Table 1. Range of chronic human oral exposures to
iAs resulting in adverse effects.
System or effect LOAEL (mg/kg/day)
Cardiovascular 0.002–0.067
Dermal 0.005–0.08
Endocrine 0.11
Gastrointestinal 0.015–0.06
Hematopoietic 0.05
Hepatic 0.006–0.1
Neurologic 0.005–0.11
Respiratory 0.015–0.08
Cancer 0.0011–3.67
LOAEL, lowest observable adverse effect level. Data
adapted from ATSDR (2000).2001; Rossman 2003). More than one of
these mechanisms may occur, and some may
work together.
Animal. The results of many cancer bio-
assays in which several species were adminis-
tered iAs in the diet or drinking water or after
oral intubation have been negative (Hughes
2002; Kitchin 2001; Rossman 2003). The
lack of an animal model for iAs-induced car-
cinogenicity has hindered determination of a
mechanism for this effect. However, recent
studies with iAs have used transgenic mice
(Chen 2000; Germolec et al. 1997), ultravio-
let radiation as a co-carcinogen (Burns et al.
2004), and in utero exposure at relatively high
doses (Waalkes et al. 2004). In these studies,
tumors have developed in the iAs-exposed
animals.
Rats administered high levels of DMAV
in the diet or drinking water developed blad-
der tumors (Arnold et al. 1999; Wei et al.
1999). DMAV is also a multiorgan tumor
promoter in rodents (Wanibuchi et al. 2004).
Hepatocellular adenomas were significantly
increased over background levels in rats
administered TMAO in drinking water (Shen
et al. 2003b). In contrast MMAV adminis-
tered in the diet (Arnold et al. 2003) or
drinking water (Shen et al. 2003a) of rodents
was not carcinogenic.
Human. Lung cancer from occupational
exposure to arsenic in smelter workers, miners,
and pesticide manufacturers has been reported
(NRC 1999; WHO 2001). Exposure to
drinking water contaminated with iAs can
lead to the development of cancer in skin,
bladder, lung, kidney, and other internal
organs (NRC 1999, 2001; WHO 2001).
Quantitative estimates for the risk of
development of skin cancer from oral expo-
sure to iAs are an oral slope factor of
1.5 mg/kg/day and a drinking water unit risk
of 5 × 10–5 µg/L (U.S. EPA 1993). The
arsenic inhalation unit risk for cancer, based
on studies of occupational exposure to iAs, is
4.3 × 10–3 µg/m3 (U.S. EPA 1993).
A National Academy of Sciences committee
analyzed the health effects of iAs in drinking
water and reported theoretical maximum-
likelihood estimates of excess lifetime risk of
bladder and lung cancer in the U.S. population
(NRC 2001). At 10 µg/L of arsenic in water,
the incidence per 105 people for bladder cancer
was 12 for females and 23 for males. The inci-
dence per 105 people for lung cancer was 18
for females and 14 for males. These risk esti-
mates are greater than those used by the U.S.
EPA in its decision to lower the arsenic drink-
ing water maximum contaminant level (MCL)
from 50 to 10 µg As/L.
Methodologies for Detection
and Speciation of Arsenic
Many techniques are available to analyze
arsenic in biological samples (B’Hymer and
Caruso 2004; Francesconi and Kuehnelt 2004;
Gong et al. 2002; Mandal et al. 2004; WHO,
2001). Methods to measure total arsenic
include neutron activation, X-ray ﬂuorescence,
atomic absorption and ﬂuorescence spectrome-
try, and inductively coupled plasma–atomic
emission and –mass spectrometry. The latter
two techniques are the most sensitive for total
arsenic measurement (picogram range). Sample
preparation can be burdensome for total
arsenic measurement using the spectroscopic
techniques. The organic arsenic in the matrix
must be converted to iAs, usually by heating
the sample to extreme temperatures in concen-
trated acid or by dry ashing.
Speciated analysis can differentiate inor-
ganic from organic arsenic, and some tech-
niques may maintain its oxidation state.
Speciated analysis is performed by coupling
chromatographic separation with a detector
used for total arsenic analysis (Table 2).
Sample preparation for speciated analysis is
not as extreme as required for total arsenic
analysis. In some cases, urine can be analyzed
directly after removal of particulates by
centrifugation.
The stability of arsenicals, particularly
trivalent species, excreted in urine is a critical
issue for speciated arsenic analysis. It is gener-
ally difﬁcult to analyze urinary arsenic at a col-
lection site. Storage of samples at 4 and –20°C
appears to be suitable for maintaining the
valence of some arsenicals for several months
(Chen et al. 2002; Feldmann et al. 1999).
Freeze-drying urine samples and storing frozen
also extends stability of arsenicals (Feldmann
et al. 1999; Yoshinaga et al. 2000).
Crecelius and Yager (1997) examined the
variability in arsenic quantitation among
several different laboratories. These laborato-
ries analyzed standard solutions of MMAV
and DMAV, a reference sample and human
urine spiked with iAsIII, iAsV, MMAV, and
DMAV. Different methods were used for
total and speciated arsenic analysis. For sam-
ples that contained < 5 µg/L arsenic, the accu-
racy and precision were poor. However, the
measurement of total iAs, MMAV, and
DMAV improved at levels > 5 µg/L, levels
relevant to human exposure.
Standard reference material for arsenic is
available in biological matrices such as urine,
muscle, and liver but is certiﬁed only for total
arsenic. Although a certiﬁed reference material
for speciated arsenic in urine has been pre-
pared (Yoshinaga et al. 2000), it is less readily
obtainable. The identity of speciﬁc arsenicals
has also become an issue. Hansen et al. (2004)
reported that an arsenic sulfur compound that
was detected in urine has been misidentiﬁed as
DMAIII. The availability of standard reference
material for arsenic, which includes the triva-
lent methylated forms, has a tremendous
impact on the ability to properly conduct an
arsenic exposure analysis if biomarkers of
exposure are to be used.
Biomarker Characterization
Arsenic biomarkers of exposure include the
analysis of urine, blood, hair, or nails for
arsenic. Detection of arsenic in these biologi-
cal samples is indicative of systemic absorption
after exposure to it. However, arsenic from
external sources may bind to hair and nails,
which can complicate the exposure analysis.
Urine. Absorbed arsenic is primarily
excreted in urine, with a half-life of approxi-
mately 4 days in humans (NRC 1999; WHO
2001). Urinary arsenic is analyzed as total or
speciated. Background levels of urinary
arsenic range from 5 to 50 µg/L (NRC 1999).
Excessive exposure to iAs in drinking water
can lead to urinary arsenic levels > 700 µg/L
(Buchet et al. 1999). For occupational expo-
sure to iAs, the recommended biologic expo-
sure determinant value is 35 µg As/L in urine
(American Conference of Governmental
Industrial Hygienists 2004). This level is a
guideline for potential workplace health
hazards and includes excreted iAs plus its
methylated metabolites.
Hughes
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Table 2. Examples of analytical techniques for speciation and detection of arsenic in urine.
Separation Detection Arsenic species Level of detection Reference
Cryogenic Hydride generation–atomic absorption spectrometry iAsIII, iAsV, MMAIII, MMAV, DMAIII,  0.14–0.4 ng Devesa et al. 2004
DMAV, TMAO
HPLC (ion pair) Hydride generation–atomic ﬂuorescence spectrometry iAsIII, iAsV, MMAIII, MMAV, DMAIII, DMAV 10–40 pg Le et al. 2000
HPLC (ion pair) Hydride generation–inductively coupled  iAsIII, iAsV, MMAV, DMAV 4–10 ng Do et al. 2000
plasma–atomic emission spectrometry
HPLC (anion exchange) Hydride generation–inductively coupled plasma  iAsIII, iAsV, MMAIII, MMAV, DMAIII,  3–7 pg Mandal et al. 2004
mass spectrometry DMAV, arsenocholine, arsenobetaine
HPLC (anion exchange) Hydride generation–atomic absorption spectrometry iAsIII, iAsV, MMAV, DMAV, TMAO 0.11–0.26 ng Sur and Dunemann 2004
HPLC, high-performance liquid chromatography.Quantitative correlations between the
concentration of arsenic in urine and in air,
water, or soil have been observed (Table 3).
Linear relationships have been determined
between urinary arsenic and iAs in water and
soil. For iAs in soil, the correlations to urinary
arsenic are less consistent; very high levels of
iAs are generally necessary for a positive corre-
lation to urinary arsenic (Valberg et al. 1997).
This relationship is inﬂuenced by arsenic geo-
chemistry and bioavailability of the arsenic in
the soil matrix. For iAs in air, linear and non-
linear relationships have been reported with
urinary arsenic. Pinto et al. (1976) reported a
linear relationship up to 150 µg/m3 of
arsenic, whereas Enterline et al. (1987)
reported a nonlinear relationship with higher
arsenic air concentrations. The nonlinear rela-
tionship was attributed to either the use of
respirators by the workers at high arsenic air
concentrations or changes in their arsenic
storage or excretion mechanisms.
Certain foods contain organic arsenicals
that can confound total urinary arsenic analy-
sis. Some seafood contains high levels of
arsenobetaine, an organic arsenical that is rel-
atively nontoxic and excreted rapidly in urine
intact (Vahter et al. 1983). Seaweed and
marine algae contain arsenosugars that are
metabolized to DMAV after consumption and
excreted in urine (Francesconi et al. 2002; Le
et al. 1994; Ma and Le 1998). Aspects relat-
ing to the metabolism of arsenosugars have
become more complex because of the recent
identification of dimethylarsenic sulfur and
acetate compounds in urine of sheep that
ingested seaweed (Hansen et al. 2003, 2004).
In an iAs exposure analysis for which seafood
ingestion is suspected, speciation of urinary
arsenic as well as determination of total uri-
nary arsenic would be critical. If only total
urinary arsenic was determined, exposure to
iAs may be overestimated. For iAs exposure
assessments, subjects should refrain from
ingesting seafood 2–3 days before collection
of urine.
Other concerns of urinary arsenic analysis
are sample collection times (24 hr, spot, ﬁrst
morning void) and whether to adjust the data
to volume of urine voided (related to urinary
creatinine levels or speciﬁc gravity). Collection
of urine for 24 hr can be difﬁcult, because of
quality assurance logistics, particularly if a
large number of samples are to be collected.
Urinary arsenic does not appear to vary over
time, so spot collection or ﬁrst morning void
may be used (Calderon et al. 1999; Hewitt
et al. 1995). In addition, intraindividual vari-
ation of iAs metabolism and its urinary excre-
tion was low over a 5-day period (Concha
et al. 2002). This suggests that methylation of
arsenic may be steady over time by an indi-
vidual who is continuously exposed to the
same level of arsenic.
Blood. Arsenic is cleared from blood
within a few hours after it is absorbed (NRC
1999). Analysis of blood for arsenic is best
suited for recent high-dose exposures.
Background arsenic blood levels range from
0.5 to 2 µg/L (NRC 1999). Even though
blood may attain steady-state levels after
chronic exposure to iAs, it may not be a reli-
able biomarker of arsenic exposure because it
is cleared so rapidly, particularly for low levels
of iAs (ATSDR 2000).
A poor relationship exists between arsenic
levels in drinking water and blood (WHO
2001). For levels of iAs in drinking water that
ranged from 2.5 to 31 µg/L in a group of
Andean women, blood arsenic levels were
< 2 µg/L, and the total urinary arsenic concen-
tration increased from 13 to 45 µg/L. In a
group exposed to 200 µg/L iAs in water, blood
arsenic levels increased to 8 µg/L, but total uri-
nary arsenic increased to 261 µg/L (Vahter
et al. 1995).
Blood is a more difficult matrix to work
with than urine, and collection of it is an
invasive procedure. Fewer subjects may par-
ticipate in a blood collection study. Total
arsenic analysis in blood may also present a
problem if seafood was consumed by the sub-
jects. Thus, if blood is to be sampled for
determination of arsenic for exposure analysis,
careful planning and a consistent sampling
strategy should be employed.
Hair and nails. Absorbed arsenic accu-
mulates in hair and nails. This is thought to
be due to the binding of AsIII to sulfhydryl
groups in keratin. Because hair and nails grow
slowly, their analysis may give an indication
of past arsenic exposure. Background arsenic
levels in hair are < 1 µg/g (Hindmarsh 2002)
and in nails range from < 1.5 to 7.7 µg/g
(Agahian et al. 1990; Hinwood et al. 2003).
iAs is the predominant form of arsenic in
hair, with small amounts of dimethylated
arsenic (Yamauchi et al. 1989). Based on
animal studies, arsenobetaine does not accu-
mulate in hair (Vahter et al. 1983), so
consumption of seafood should not be a com-
plicating factor in arsenic hair analysis.
Increased concentrations of arsenic in hair
are observed in populations exposed to elevated
levels of iAs in drinking water (Hinwood et al.
2003; Kurttio et al. 1998), air (Yamauchi et al.
1989), and soil (Hinwood et al. 2003). Kurttio
et al. (1998) reported a signiﬁcant correlation
between arsenic in hair with total urinary
arsenic (r = 0.75, p < 0.001), arsenic in drinking
water (r = 0.74, p < 0.001), and daily dose of
arsenic (r = 0.77, p < 0.001). With an increase
of 10 µg/L of arsenic in drinking water, arsenic
in hair increased 0.1 µg/g.
Populations exposed to elevated levels of
iAs in drinking water (Hinwood et al. 2003),
air (Agahian et al. 1990), and soil (Hinwood
et al. 2003) show increased levels of arsenic in
nails. Karagas et al. (1996) reported a signiﬁ-
cant correlation between detectable levels of
arsenic in drinking water (> 1 µg/L) and in
toenails (r = 0.83, p = 0.0001). With a 10-fold
increase in arsenic in well water, the toenail
arsenic concentration increased about 2-fold.
In a follow-up study with a larger sample size,
a signiﬁcant correlation (r = 0.46, p < 0.001)
between arsenic in water (0.002–66.6 µg/L)
and nails (< 0.01–0.81 µg/g) was observed
(Karagas et al. 2000).
The collection of hair and nails is not as
invasive as collecting blood; more subjects may
be willing to participate in iAs exposure studies
if hair and nails are collected. A major issue in
the use of hair and nails as biomarkers of expo-
sure is their adsorption of arsenic from external
sources (Hindmarsh 2002). For someone who
consumes and bathes in water or is in contact
with soil with elevated levels of iAs, arsenic
from internal and external exposure would
most likely be detected in hair and nails. This
would complicate the exposure analysis.
Although washing procedures have been devel-
oped, the possibility exists that this procedure
may remove arsenic in the specimens that orig-
inated from internal sources. It is also not
presently possible to distinguish between exter-
nally and internally derived arsenic in hair
(Hindmarsh 2002).
Exposure Assessment
Food and drinking water are the principal
sources of nonoccupational exposure to iAs
Biomarkers of arsenic exposure
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Table 3. Quantitative relationships between the concentration of arsenic in exposure media and in urine or nails.
Exposure media Biologic sample Quantitative relationship Reference
Air (3–295 µg As/m3) Urine (µg/L) Cair = 0.3Curine (p < 0.01, r = 0.53) Pinto et al. 1976
Air (50–3,500 µg As/m3) Urine (µg/L) Cair = 0.0064(Curine)1.94 Enterline et al. 1987
Air (< 0.1–35 µg As/m3) Nails (µg/g) Cair = 1.79Cnail–5.9 Agahian et al. 1990
Water (8–620 µg As/L) Urine (µg/mg creatinine) 10–2.57(Cwater)0.63 = logCurine (p < 0.001, r = 0.655) Calderon et al. 1999
Soil (102–356 µg As/g) Urine (µg/L) 0.1955(logCsoil) + 0.4818 = logCurine (p < 0.001, r = 0.25) Hwang et al. 1997
Soil (9–139 µg As/g) Urine (µg/L) 3.025(Csoil)0.237 = Curine (p< 0.01, r= 0.21) Ranft et al. 2003for most populations. The daily dietary intake
of iAs for an adult in the United States ranges
from 8 to 14 µg/day (Yost et al. 1998).
Approximately 98% of the U.S. population
ingests water containing < 10 µg As/L
(Chappell et al. 1997). Thus, the nonoccupa-
tional exposure to iAs in most of the adult
U.S. population (regular diet and 2 L of
water/day) is < 50 µg/day. There are regions
in the United States and the world where
arsenic levels in drinking water are signifi-
cantly elevated. If this water is regularly
ingested, exposure to iAs would be signifi-
cantly increased. Other sources of iAs expo-
sure are soils at Superfund sites and where
arsenical pesticides were produced or used.
Wolz et al. (2003) reported on elevated levels
of arsenic in and around homes constructed
on or near fruit orchards in agricultural com-
munities with historical use of lead arsenate.
This study showed strong correlations
between indoor and outdoor concentrations
of arsenic and hence provided evidence for a
“track-in” exposure pathway for residential
environments. Occupational exposure of
arsenic can occur at smelters, coal burning
facilities, or arsenic pesticide manufacturing
sites via inhalation. Populations that reside
near these industries also have the potential
for exposure to arsenic.
Walker and Grifﬁn (1998) used an expo-
sure assessment model (U.S. EPA 1989) to
predict urinary arsenic concentrations of chil-
dren living near a Superfund site. Using this
model and site-specific data, the predicted
urinary arsenic concentrations reasonably
agreed with the measured urinary arsenic con-
centrations. The predicted risks from expo-
sure to iAs using the site-speciﬁc data in the
exposure model were less than those predicted
risks using default values. The results of this
study, which used biomonitoring data, show
that current risk assessment approaches using
default values can be conservative by over-
estimating risk.
Evaluation of trends in exposure. Analysis
of urine and blood is typically used for recent
exposure to iAs. This is because arsenic is
rapidly cleared from the blood and excreted in
the urine after its systemic absorption (NRC
1999). Hair and nails may be used to assess
past exposure to iAs. A major question in the
use of urinary arsenic as a biomarker of expo-
sure is how to relate the recent exposure, mea-
sured by urinary arsenic, to exposures that may
have occurred chronically. Sporadic episodes of
higher exposures within a chronic exposure
context are also difﬁcult to determine.
Uniquely exposed populations. There are
populations in India, Bangladesh, and other
countries that are exposed to exceedingly high
levels of iAs in their drinking water
(Chatterjee et al. 1995; Nordstrom 2002).
Children also represent a subgroup for unique
exposure to iAs. Children differ from adults
in that they are still developing and have dis-
similar food and water consumption patterns
and exposure to media, such as soil and CCA-
treated wood, which may have a significant
impact on the total exposure. Polissar et al.
(1990) examined pathways of arsenic expo-
sure in a population that resided near a cop-
per smelter. These pathways included
outdoor and indoor air, soil, and house dust.
Elevated urinary arsenic levels were found pri-
marily in children younger than 6 years who
lived within 0.5 miles of the smelter. Hand-
to-mouth activity appeared to be the main
source of arsenic exposure to these children.
In utero exposure to iAs, primarily from
mothers consuming elevated iAs in drinking
water, may represent another unique type of
exposure. Knowledge of the effects of this
type of exposure is limited, although elevated
adverse pregnancy outcomes (e.g., stillbirths)
have been reported in Bangladeshi women
chronically exposed to iAs in drinking water
(Ahmad et al. 2001).
Effectiveness of an Intervention
or Regulatory Action
The actions of governmental and nongovern-
mental organizations (Chowdhury 2004;
Smith et al. 2000) that are attempting to
reduce the drinking water exposure of iAs in
the Bangladesh population are an example of
the conﬁrmed relationship of arsenic exposure,
biomarkers, and health effects. Because of the
relationship between drinking water exposure
to iAs and development of cancer, the U.S.
EPA lowered the arsenic drinking water MCL
from 50 to 10 µg/L (U.S. EPA 2001). The
U.S. Food and Drug Administration (2005)
recently revised the bottled water quality stan-
dard at the same level. The WHO lowered its
recommended arsenic drinking water guideline
from 50 to 10 µg/L in 1993.
Approximately 2% of the U.S. population
will be above the revised MCL for arsenic in
2006. One way to follow the effectiveness of
this MCL would be to analyze urinary arsenic
from a segment of this population after their
arsenic drinking water levels are decreased.
Hopenhayn-Rich et al. (1996) analyzed urine
from a population previously exposed to high
iAs (600 µg/L) drinking water levels and had
switched to water containing less arsenic
(45 µg/L). The average urinary arsenic levels
in this population decreased from 636 to
166 µg As/L.
Conclusions and
Recommendations 
for Future Research
iAs is a ubiquitous environmental contami-
nant. Human exposure to it occurs from
many types of media. Analytical techniques
have been developed that can detect low levels
of iAs in biologic samples. Based on the oral
RfD and drinking water MCL, it appears that
there are levels of iAs that most humans can
be exposed to without the development of
adverse outcomes. However, many questions
about iAs still exist, and the recommendations
listed below may aid in decreasing these
uncertainties:
• Link biomarkers of arsenic exposure to effect.
• Standardize a method for arsenic species
analysis in biological samples that ensures
good quality assurance and control and con-
siders stability issues after sample collection.
• Determine the mechanism of action for
arsenic.
• Examine the intra- and interindividual vari-
ability of arsenic methylation and effect.
• Assess the efficacy of lowering the arsenic
drinking water MCL from 50 to 10 µg/L.
• Understand the magnitude and duration of
exposure to iAs.
• Develop physiologically based pharmacoki-
netic models for iAs low-dose extrapolation.
• Quantify the contribution of arsenosugars
to dimethylarsenic levels in urine.
• Assess contribution of arsenic in diet to
overall exposure.
Many of the studies referenced here have
observed a signiﬁcant and positive correlation
between iAs in an exposure medium and
arsenic in a biologic sample, principally urine,
hair, and nails. With proper precautions and
recognition of their limitations, analysis of
these samples can be informative regarding
whether an exposure to iAs occurred. It
would be ideal if the biomarkers of exposure
for iAs were linked to target tissue dose and,
perhaps more important, to an adverse health
effect in humans. For example, Enterline
et al. (1987) reported a linear relationship
between respiratory cancer mortality based on
standardized mortality ratios and total urinary
arsenic in smelter workers. More studies like
Enterline et al. (1987) as well as in other areas
are needed to develop a more robust risk
assessment for iAs and enhance public health
protection.
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